SciCann Therapeutics

Reaching beyond the unknown boundaries of cannabinoid science

Canada - israel

A bridging link between the thriving cannabis ecosystems of Canada and Israel


SCICANN THERAPEUTICS Reaching beyond the unknown boundaries of cannabinoid science


Most advanced and fastest growing cannabis market in the world.


World leader in cannabis and cannabinoid R&D

SciCann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system.

SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of chosen life- threatening conditions that present a high level of unmet need.

SciCann Therapeutics holds a diversified portfolio of IP and ownerships in ventures operating in the cutting edge technology of cannabinoid science, and maintains a wide network of strategic and synergistic collaborations with leading research institutes and commercial companies in the space.


Rational for operating in the cannabinoid pharmaceutical space

The Cannabis plant contains over 400 pharmaceutically active compounds, most of which have never been studied for their profound therapeutic effects.

Recent studies suggest that unique and synergistic cannabinoid combinations may have a high therapeutic potential in almost all diseases affecting humans, including cancer, neurodegenerative diseases, auto-immune disorders, and many more.

Experts estimate that cannabinoid based drugs can replace up to 30%-40% of existing prescription drug consumption in the near future.


SciCann Therapeutics is dedicated to the discovery and development of novel and proprietary technologies in the cannabinoid space, including new therapeutic agents, drug candidates, novel cannabis genetics, personalized treatment tools and more.

Business strategy

R&D in Israel – Commercialization in Canada

Business strategy

R&D in Israel – Commercialization in Canada

SciCann Therapeutics is bridging the gap between Israel’s strong R&D capabilities in the field of cannabinoid science and Canada’s booming medical cannabis markets.

SciCann Therapeutics is collaborating with Israel’s leading research labs and medical centers, and commercializing its resulting innovative and proprietary products in leading international markets, focusing initially on the strong medical cannabis market in Canada.

the team

Zohar Koren, PhD


An experienced entrepreneur and inventor in the pharmaceutical and medical cannabis fields.
Co-founder, director and CEO of Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a developer of novel medical cannabis formulations and products, established in 2012.

read more»

VP BD of Mor Research applications – the commercial arm of Clalit Healthcare Services.

Director of BD at Aposense Ltd (TASE:APOS) – a speciality pharma company in the oncology field.

Veteran of the prestigious IDF Talpiyot project, holds a PhD in the fields of molecular and computational biology.

«read less

Daniel N. Bloch, B.Comm., LL.B.

VP BD and General Counsel

An expert in international corporate finance, mergers and acquisitions, joint ventures, private equity and securities law.
member of the Law Society of Canada and a registered Foreign Lawyer with the Israeli Bar Association.

read more»

Was involved in transactions in excess of $3B in over 20 countries worldwide, in various industry sectors including biotechnology, healthcare and natural resources.

Served as an officer and director of various Canadian and U.S. publicly listed companies and is a member of the Association of International Negotiators.

«read less

Gadi Levin, CA (SA), MBA


CPA with over 20 years experience in public and private companies, proven experience in multi-million dollars cross border transactions.

read more»

Mr. Gadi Levin is a qualified chartered accountant with over 20 years of experience in his field, including as CFO of North American publicly listed companies: Eco Atlantic Oil and Gas Ltd, BriaCell Therapeutics Corp., Enthusiast Gaming Holdings Inc and Vaxil Bio Ltd. Eco Atlantic is also listed on the AIM in London. Gadi also serves on the board of directors of Eco Atlantic and Vaxil Bio Ltd. In addition, Gadi provides outsourced CFO and financial and accounting services to private start-up companies.
In the past, Mr. Levin also acted as CFO of Labstyle Innovations Ltd (now Dario Health Corp), a mobile health company focused on diabetes and listed on NASDAQ. Mr. Levin served as the Vice President of Finance and CFO for two Israeli investment houses in the fields of private equity, hedge funds and real estate (2008 – 2009 and 2010, respectively). Prior to that, Mr. Levin acted as financial consultant to various copmanies.
Mr. Levin began his career at the accounting firm Arthur Andersen, where he worked in the Cape Town, London, and Tel Aviv offices for nine years. He holds a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a post-graduate degree in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel.

«read less

Alan Friedman

Canadian capital markets advisor

Founder and CEO of Rivonia Capital, a Canadian finance and capital markets advisory firm specializing in the cannabis space.
Co-founder of capital pool corporation, which took the Cronos Group public into the TSXV.

read more»

Advisor to a number of private companies in the cannabis space and Co-founder of several publicly traded companies across diversified industries.

«read less

Prof. Dan Peer

Head of Scientific Advisory Board

Chairman of Tel Aviv University Cancer Biology Research Center – the biggest Cancer Center in Israel that includes 17 affiliated hospitals.

read more»

Director of the Laboratory of Precision NanoMedicine at Tel Aviv University.

Director of Israel’s national nanomedicine initiative project.

Director of Leona M. and Harry B. Helmsley Nanotechnology Research Fund.

«read less



SciCann Therapeutics receives notice of allowance for its enhanced CBD therapy US patent for NASH


SciCann Therapeutics launch liver disease research program in Tel Aviv University


FSD Pharma and SciCann Therapeutics to Present at the iCDP Summit in Boston


SciCann Therapeutics Announces Positive ISA Report for “Steady Stomach” CBD Combination Therapy Patent


FSD Pharma Announces Launch of IBS Clinical Study


FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University


SciCann Therapeutics reports positive pre-clinical results for proprietary CBD combination product


FSD Pharma reports positive pre-clinical results for proprietary CBD combination product


FSD Pharma and SciCann Therapeutics Launch Clinical Research Program in Israel


FSD Pharma secures exclusive rights in Canada for line of proprietary products and premium access to cannabinoid science research platform in Israel


69 Yonge St. , Suite 1010
Toronto, Ontario

Reaching beyond the unknown boundaries of cannabinoid science

SciCann Therapeutics

Canadian Pacific Building, 69 Yonge St, Toronto Canada